JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 100 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,861 | -22.8% | 1,650 | 0.0% | 0.00% | – |
| Q2 2022 | $5,000 | -55.4% | 1,650 | 0.0% | 0.00% | – |
| Q1 2022 | $11,204 | -18.7% | 1,650 | 0.0% | 0.00% | – |
| Q4 2021 | $13,778 | +12.4% | 1,650 | 0.0% | 0.00% | – |
| Q3 2021 | $12,260 | +9.3% | 1,650 | 0.0% | 0.00% | – |
| Q2 2021 | $11,220 | -33.8% | 1,650 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $16,946 | +34.5% | 1,650 | -8.3% | 0.00% | 0.0% |
| Q4 2020 | $12,600 | -14.2% | 1,800 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $14,688 | +3.8% | 1,800 | -12.2% | 0.00% | 0.0% |
| Q2 2020 | $14,145 | +86.1% | 2,050 | +28.1% | 0.00% | 0.0% |
| Q1 2020 | $7,600 | -35.5% | 1,600 | +18.5% | 0.00% | 0.0% |
| Q4 2019 | $11,786 | +489.9% | 1,350 | +125.0% | 0.00% | – |
| Q3 2019 | $1,998 | -32.7% | 600 | 0.0% | 0.00% | – |
| Q2 2019 | $2,970 | -56.5% | 600 | -45.5% | 0.00% | -100.0% |
| Q1 2019 | $6,820 | +84.0% | 1,100 | 0.0% | 0.00% | – |
| Q4 2018 | $3,707 | -48.2% | 1,100 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $7,150 | -15.1% | 1,100 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $8,426 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |